학술논문
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFRT790M-Mutated NSCLC That Had Progressed After Prior EGFRTyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
Document Type
Article
Author
Lu, Shun; Zhang, Yiping; Zhang, Guojun; Zhou, Jianying; Cang, Shundong; Cheng, Ying; Wu, Gang; Cao, Peiguo; Lv, Dongqing; Jian, Hong; Chen, Chengshui; Jin, Xiangming; Tian, Panwen; Wang, Kai; Jiang, Guanming; Chen, Gongyan; Chen, Qun; Zhao, Hui; Ding, Cuimin; Guo, Renhua; Sun, Guoping; Wang, Bin; Jiang, Liyan; Liu, Zhe; Fang, Jian; Yang, Junquan; Zhuang, Wu; Liu, Yunpeng; Zhang, Jian; Pan, Yueyin; Chen, Jun; Yu, Qitao; Zhao, Min; Cui, Jiuwei; Li, Dianming; Yi, Tienan; Yu, Zhuang; Yang, Yan; Zhang, Yan; Zhi, Xiuyi; Huang, Yunchao; Wu, Rong; Chen, Liangan; Zang, Aimin; Cao, Lejie; Li, Qingshan; Li, Xiaoling; Song, Yong; Wang, Donglin; Zhang, Shucai; Ding, Lieming; Zhang, Ling; Yuan, Xiaobin; Yao, Lin; Shen, Zhilin
Source
Journal of Thoracic Oncology; October 2022, Vol. 17 Issue: 10 p1192-1204, 13p
Subject
Language
ISSN
15560864; 15561380
Abstract
Befotertinib (D-0316) is a novel, third-generation EGFRtyrosine kinase inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or metastatic NSCLC who developed an EGFRT790M mutation after progression on first- or second-generation EGFRTKI therapy.